Articles
Comparisons

Retatrutide vs Survodutide: Weight Loss, Side Effects and Status Compared

How retatrutide and survodutide compare in their Phase 3 trials: weight loss on the same basis, side effects and how many stopped, heart and liver data, and where each drug stands with regulators.

Written By
retaweightloss.com
Updated on
19 Nov 2026
Time to read
5 min read
Category
Comparisons
Retatrutide vs survodutide: Phase 3 weight loss and safety compared

Retatrutide vs Survodutide: Weight Loss, Side Effects and Status Compared

How retatrutide and survodutide compare in their Phase 3 trials: weight loss on the same basis, side effects and how many stopped, heart and liver data, and where each drug stands with regulators.

By
RetaWeightLoss.com
Created on:
19 Nov 2026
Updated on:
19 Nov 2026
Share this post

Retatrutide vs Survodutide: The Short Answer

Retatrutide and survodutide have never been tested against each other. In their separate Phase 3 trials in adults with obesity and without diabetes, retatrutide produced considerably more weight loss on the same basis, and fewer participants stopped it because of side effects. On the highest dose, weight fell by 25.0% at 80 weeks on retatrutide and by 13.0% at 76 weeks on survodutide, counting everyone randomized, or by 28.3% and 16.6% if taken as intended. About one in four participants on survodutide stopped treatment because of adverse events, against about one in nine on the highest dose of retatrutide.

Survodutide is further along in two areas. It has completed a large cardiovascular safety trial, which found no increase in major cardiovascular events against placebo, and it has biopsy-based results in MASH, the inflammatory form of fatty liver disease. Retatrutide has neither yet. Both drugs are investigational, neither is approved anywhere, and both developers have said they plan to file in obesity in 2027.

What Are Retatrutide and Survodutide?

Both are once-weekly injections that act on the glucagon receptor together with the GLP-1 receptor, the target of semaglutide. Retatrutide, developed by Eli Lilly, also acts on a third receptor, GIP, the second target of tirzepatide, which makes it a triple agonist. Survodutide, developed by Boehringer Ingelheim under license from Zealand Pharma, is a dual glucagon/GLP-1 agonist and does not act on GIP.

The Phase 3 trials compared here tested retatrutide at 4, 9 and 12 mg and survodutide at 3.6 and 6.0 mg. The doses are not interchangeable: they are different molecules, and a milligram of one says nothing about a milligram of the other. Neither trial program was designed to show which receptor accounts for which effect.

Weight Loss in People Without Diabetes: TRIUMPH-1 vs SYNCHRONIZE-1

The two trials that are closest in design enrolled adults with obesity, or overweight with a weight-related condition, and without diabetes. Both report results in two ways: counting everyone randomized, whether or not they kept taking the drug (the treatment-regimen estimand), and estimating the effect had everyone stayed on treatment (the efficacy estimand). The comparison below keeps the two apart; why they differ is explained in why retatrutide weight loss numbers differ.

Adults with obesity or overweight, without diabetes Retatrutide (TRIUMPH-1) Survodutide (SYNCHRONIZE-1)
Participants 2,339 725
Length 80 weeks 76 weeks
Doses tested 4, 9 and 12 mg weekly 3.6 and 6.0 mg weekly
Weight loss on the highest dose, everyone randomized (placebo) 25.0% (3.9%) 13.0% (5.4%)
Weight loss on the highest dose, if taken as intended (placebo) 28.3% (2.2%) 16.6% (3.2%)
Lost at least 20% of body weight, highest dose, everyone randomized (placebo) 66.8% (6.4%) 28.5% (6.6%)
Stopped because of adverse events, highest dose (placebo) 11.2% (4.6%) 24.8% (5.4%)


All figures come from the two published papers in the New England Journal of Medicine. On the lower doses, weight fell by 12.2% on survodutide 3.6 mg, counting everyone randomized; in TRIUMPH-1, retatrutide gave 17.6% on 4 mg and 23.7% on 9 mg on the same basis. Placebo groups lost some weight in both trials, more in SYNCHRONIZE-1 (5.4%) than in TRIUMPH-1 (3.9%), so the difference from placebo is also worth comparing: about 21 percentage points for retatrutide 12 mg and about 8 for survodutide 6.0 mg, counting everyone randomized. These differences are our calculation from the published figures.

The trials were not identical. TRIUMPH-1 ran four weeks longer, its participants started at an average of 112.7 kg against 108.8 kg in SYNCHRONIZE-1, and the two used different dose-escalation schemes. In SYNCHRONIZE-1, dose adjustments were initially allowed only between weeks 16 and 32, and participants had to stop treatment if they missed three or more doses; a protocol amendment in February 2025 allowed treatment to be restarted, but by then most participants were more than three quarters of the way through treatment. These differences mean the comparison is approximate.

Weight Loss in Type 2 Diabetes: TRIUMPH-2 vs SYNCHRONIZE-2

Weight loss is usually smaller in people with type 2 diabetes, and that held for both drugs. TRIUMPH-2 and SYNCHRONIZE-2 enrolled adults with obesity or overweight and type 2 diabetes; more on retatrutide in this group is in retatrutide for type 2 diabetes.

Adults with obesity or overweight and type 2 diabetes Retatrutide (TRIUMPH-2) Survodutide (SYNCHRONIZE-2)
Participants 1,152 755
Length 80 weeks 76 weeks
Weight loss on the highest dose, everyone randomized (placebo) 18.8% (5.1%) 9.8% (3.9%)
Weight loss on the highest dose, if taken as intended (placebo) 20.8% (4.0%), company announcement 13.1% (3.1%)
Stopped because of adverse events, highest dose (placebo) 7.7% (4.9%), company announcement 25.9% (8.8%)


The survodutide figures come from the SYNCHRONIZE-2 paper in the New England Journal of Medicine. For TRIUMPH-2, the treatment-regimen figures come from the summary of the paper in The Lancet, and the efficacy figure and the share who stopped from the company's announcement, which gave 7.7% on 12 mg and 11.6% on 9 mg, against 4.9% on placebo. The pattern was similar to the one in people without diabetes: about 14 percentage points from placebo for retatrutide 12 mg and about 6 for survodutide 6.0 mg, counting everyone randomized (our calculation). In SYNCHRONIZE-2, counting everyone randomized, HbA1c fell by 0.9 and 0.8 percentage points on 3.6 mg and 6.0 mg, against 0.2 on placebo, from an average of 7.4%.

Side Effects and How Many People Stopped

For both drugs, the most common side effects were gastrointestinal, and they were reported more often on survodutide. The table compares the highest doses in the two trials without diabetes; the full retatrutide data are in retatrutide side effects.

Adverse event, highest dose (placebo in parentheses) Retatrutide 12 mg (TRIUMPH-1, 80 weeks) Survodutide 6.0 mg (SYNCHRONIZE-1, 76 weeks)
Nausea 42.4% (14.8%) 64.9% (17.4%)
Vomiting 25.3% (4.8%) 44.6% (6.2%)
Diarrhea 32.0% (13.5%) 39.7% (18.6%)
Constipation 26.1% (10.9%) 32.6% (12.4%)
Stopped because of gastrointestinal adverse events 4.6% (1.2%) 20.2% (2.9%)
Dysesthesia (altered skin sensation) 12.5% (0.9%) 2.5% (0.8%)
Low blood pressure 8.8% (0.9%) 7.4% (1.7%)
Serious adverse events 10.5% (5.5%) 8.3% (6.2%)
Change in heart rate at the end of treatment +2.6 bpm (−0.3) +3.2 to +3.5 bpm across both doses (−0.4)


The biggest difference is in how many people stopped. In SYNCHRONIZE-1, 23.7% on 3.6 mg and 24.8% on 6.0 mg stopped survodutide because of adverse events, most of them gastrointestinal, against 5.4% on placebo. In TRIUMPH-1, 4.1%, 6.5% and 11.2% stopped retatrutide on 4 mg, 9 mg and 12 mg, against 4.6% on placebo. The pattern was similar in type 2 diabetes. In announcing SYNCHRONIZE-2, Boehringer Ingelheim said discontinuations in that trial usually occurred during dose escalation, as the protocol allowed limited flexibility to manage adverse events; it said the same of SYNCHRONIZE-CVOT.

One side effect runs the other way. Dysesthesia, an altered sense of touch, was reported far more often on retatrutide: 12.5% on 12 mg in TRIUMPH-1, against 2.5% to 3.7% on survodutide in SYNCHRONIZE-1, with placebo rates below 1% in both. Low blood pressure was more common than on placebo with both drugs, although the trials grouped it differently: the TRIUMPH-1 figure counts hypotension, orthostatic hypotension and decreased blood pressure, and the SYNCHRONIZE-1 figure counts hypotension including fainting.

Both drugs raised heart rate slightly. At the end of treatment, the average pulse was 1.5 to 2.7 beats per minute higher than at the start on retatrutide, depending on the dose, and 3.2 to 3.5 higher on survodutide; it fell slightly on placebo in both. What the retatrutide trials show about heart rate is in why retatrutide increases heart rate.

Rarer events were few in both trials. In SYNCHRONIZE-1, gallstones were reported in 1.2% and 2.1% of participants on the two survodutide doses against 0.4% on placebo, and there were no adjudicated cases of acute pancreatitis and no deaths. In TRIUMPH-1, severe or serious gallbladder disorders occurred in 0.7% to 1.7% on retatrutide, depending on the dose, against 0.7% on placebo, and adjudicated pancreatitis in 8 participants on retatrutide and 2 on placebo; 4 deaths were reported among participants on retatrutide and 2 on placebo. The two papers count these events differently, and trials of this size cannot show how often rare events occur.

Heart Safety: SYNCHRONIZE-CVOT vs TRIUMPH-3

Survodutide has completed a dedicated cardiovascular safety trial; retatrutide has not yet.

Cardiovascular data Retatrutide (TRIUMPH-3) Survodutide (SYNCHRONIZE-CVOT)
Type of trial Weight-loss trial with a pre-specified analysis of cardiovascular events Event-driven cardiovascular safety trial
Who took part 1,949 adults with a BMI of 35 or more and established cardiovascular disease About 5,500 adults with overweight or obesity and cardiovascular disease, chronic kidney disease or cardiovascular risk factors
Broader composite of cardiovascular events, hazard ratio (95% CI) 0.82 (0.55 to 1.22) 0.89 (0.67 to 1.18), non-inferior to placebo
Cardiovascular death, heart attack or stroke, hazard ratio (95% CI) 1.12 (0.64 to 1.96) 0.84 (0.60 to 1.18)
Dedicated cardiovascular trial TRIUMPH-Outcomes, about 10,000 adults, listed to February 2029 Completed safety trial; published in The Lancet in November 2026


SYNCHRONIZE-CVOT, published in The Lancet in November 2026, was designed to rule out an increase in cardiovascular risk, and it did: survodutide was non-inferior to placebo for a five-part measure covering cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularization and heart failure events. Because the confidence intervals include 1, the trial does not show that survodutide lowers cardiovascular risk.

For retatrutide, the closest data come from TRIUMPH-3, a weight-loss trial in people with established cardiovascular disease that counted cardiovascular events in a pre-specified analysis. There were too few events to show a difference from placebo in either direction, and its broader measure also counted death from any cause, so it is not defined the same way as survodutide's. A dedicated outcomes trial, TRIUMPH-Outcomes, is designed to test whether retatrutide lowers serious heart-related complications and is listed as running until February 2029. The retatrutide data are covered in retatrutide and heart health.

Blood pressure differed too. In TRIUMPH-1, systolic blood pressure fell by 10.4 mmHg on retatrutide 12 mg against 1.9 mmHg on placebo. In SYNCHRONIZE-1, it fell by 5.4 mmHg on survodutide 6.0 mg and 5.9 mmHg on placebo, a difference that was not significant; in the larger SYNCHRONIZE-CVOT, the company reported a fall of up to 6.7 mmHg against 1.8 mmHg on placebo at 72 weeks, using a supplementary estimand.

Fatty Liver and MASH

Both drugs act on the glucagon receptor, which is found in the liver, and both have been studied in fatty liver disease, but at different depths.

  • Survodutide in MASH, with biopsies. In a 48-week Phase 2 trial in which 293 adults with biopsy-confirmed MASH and fibrosis received treatment, published in the New England Journal of Medicine in 2024, MASH improved without worsening of fibrosis in 47%, 62% and 43% of participants on 2.4 mg, 4.8 mg and 6.0 mg, against 14% on placebo; fibrosis improved by at least one stage in 34% to 36% against 22%, a secondary result that was not adjusted for multiple comparisons and cannot be taken as a definitive treatment effect. The FDA granted survodutide Breakthrough Therapy designation for MASH in September 2024, and two Phase 3 MASH trials, LIVERAGE and LIVERAGE-Cirrhosis, are under way.
  • Survodutide and liver fat. In SYNCHRONIZE-MASLD, a 48-week Phase 3 trial that randomized 218 adults with obesity or overweight and fatty liver disease with signs of inflammation or fibrosis, liver fat fell by at least 30% in 84.2% of participants on 6.0 mg against 24.3% on placebo, and reached normal levels in 61.0% against 5.7%, if taken as intended; counting everyone randomized, the 30% figure was 68.5% against 28.6%.
  • Retatrutide and liver fat. In a Phase 2a substudy of 98 adults with obesity and fatty liver disease, liver fat fell by 82.4% after 24 weeks on 12 mg, and 86% of participants on that dose reached normal levels; at 48 weeks the figure was 93%, although only 9 participants on that dose had a liver scan at 48 weeks. The study took no biopsies, so it could not show effects on inflammation or fibrosis. The data are in retatrutide and fatty liver.

The studies used different populations, doses and measures, so the liver fat figures cannot be compared directly. What is clear is that survodutide has biopsy evidence in MASH and retatrutide does not yet. SYNERGY-Outcomes, a Phase 3 trial testing retatrutide and tirzepatide against placebo in about 4,500 adults with fatty liver disease at higher risk of liver complications, is listed as running until August 2032.

Approval Status: Where Each Drug Stands

  • Retatrutide is not approved for any use. Its developer plans to submit a Biologics License Application to the FDA in the first quarter of 2027; on October 2, 2026, the FDA said retatrutide is not a biological product, so an application would need to be submitted under section 505 of the Federal Food, Drug, and Cosmetic Act, the pathway for new drugs. We found no ruling yet on the company's court appeal. The details are in retatrutide FDA approval status.
  • Survodutide is not approved for any use. After SYNCHRONIZE-CVOT reported on November 9, 2026, Boehringer Ingelheim said it was moving forward with global regulatory submissions in obesity. Zealand Pharma, which licensed survodutide to Boehringer Ingelheim, said on November 12, 2026 that these submissions are planned for 2027.

We found no statement from either company on when its drug might be available. Neither company has said it has submitted an application yet, so no review timeline exists for either.

What These Trials Cannot Tell Us

  • Which drug works better for a given person. There is no head-to-head trial; every comparison on this page is across separate trials with different participants, lengths and dose-escalation schemes.
  • Whether survodutide's high discontinuation rate would fall with the more flexible dose escalation the company says its upcoming trials use.
  • Whether either drug reduces heart attacks or strokes. SYNCHRONIZE-CVOT showed safety, not benefit, and retatrutide's outcomes trial has not reported.
  • Long-term safety over years of treatment.

Retatrutide vs Survodutide: The Summary

In separate Phase 3 trials, retatrutide produced substantially more weight loss than survodutide, and fewer participants stopped it because of side effects, although survodutide's trials restricted dose adjustments: on the highest doses in people without diabetes, 25.0% against 13.0% weight loss counting everyone randomized, and 11.2% against 24.8% who stopped because of adverse events. Dysesthesia was reported less often on survodutide, and it leads on two other fronts: a completed cardiovascular safety trial and biopsy-based results in MASH. Neither drug is approved, both developers have said they plan to file in obesity in 2027, and only a head-to-head trial could show how they compare directly.

Sources

  • le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. Published June 7, 2026; updated July 23, 2026. DOI: 10.1056/NEJMoa2600751. (SYNCHRONIZE-1)
  • Wharton S, le Roux CW, Startseva E, et al. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. N Engl J Med. Published October 1, 2026. DOI: 10.1056/NEJMoa2607219. (SYNCHRONIZE-2)
  • Kaplan L, et al. Survodutide in adults with obesity and metabolic dysfunction–associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026. DOI: 10.1038/s41591-026-04479-3.
  • Bozkurt B, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, phase 3 trial. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)02140-9.
  • Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. Published June 7, 2024. DOI: 10.1056/NEJMoa2401755.
  • Boehringer Ingelheim. Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity. June 7, 2026.
  • Boehringer Ingelheim. Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes. October 1, 2026.
  • Boehringer Ingelheim. Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits. November 9, 2026.
  • Zealand Pharma. Zealand Pharma Announces Financial Results for the First Nine Months of 2026. Company announcement No. 56/2026. November 12, 2026.
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Supplementary Appendix, Table S12. N Engl J Med. 2026.
  • Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Published September 2026. DOI: 10.1016/S0140-6736(26)01861-1.
  • Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026. (TRIUMPH-2 and TRIUMPH-3)
  • Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. DOI: 10.1038/s41591-024-03018-2.
  • ClinicalTrials.gov. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). NCT06383390.
  • ClinicalTrials.gov. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes). NCT07165028.
  • U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Letter to Eli Lilly and Company on remand regarding retatrutide. October 2, 2026.
  • Lilly Medical Information. Is retatrutide available in the consumer market?
  • Eli Lilly. What to know about retatrutide.

Medical Disclaimer: This article summarizes published clinical trial results for general information only and is not medical advice. Retatrutide and survodutide are investigational and are not approved by the FDA for any use. Retatrutide is not available by prescription, and Lilly says no one can legally sell it for human use. Nothing here is a recommendation to use, seek out or avoid any medication.

Frequently asked questions

Is survodutide better than retatrutide?

The two have not been compared in the same trial. In separate Phase 3 trials in people without diabetes, the highest dose of retatrutide reduced weight by 28.3% at 80 weeks and the highest dose of survodutide by 16.6% at 76 weeks, if taken as intended, and fewer people stopped retatrutide because of side effects (11.2% against 24.8%), although the survodutide trial restricted dose adjustments. Survodutide has completed a cardiovascular safety trial and has biopsy results in MASH, which retatrutide does not yet have. Neither is approved.

What is survodutide?

Survodutide is an investigational once-weekly injection that acts on the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim under license from Zealand Pharma. It has completed Phase 3 trials in obesity, obesity with type 2 diabetes, liver fat in people with obesity and fatty liver disease, and cardiovascular safety; Phase 3 trials in MASH are ongoing. It has not been approved for any use. Retatrutide acts on the same two receptors and also on GIP.

How much weight did people lose on survodutide?

In SYNCHRONIZE-1, in adults with obesity or overweight and without diabetes, weight fell by 12.2% on 3.6 mg and 13.0% on 6.0 mg at 76 weeks, counting everyone randomized, against 5.4% on placebo, or by 15.3% and 16.6% if taken as intended. In SYNCHRONIZE-2, in people with type 2 diabetes, the figures were 8.2% and 9.8% counting everyone randomized, and up to 13.1% if taken as intended.

Is survodutide FDA approved?

No. Survodutide has not been approved for any use. After its cardiovascular safety trial reported in November 2026, Boehringer Ingelheim said it was moving forward with global regulatory submissions in obesity, which its licensing partner Zealand Pharma said are planned for 2027. Retatrutide is not approved either; its developer plans to submit it to the FDA in the first quarter of 2027.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.